(1) Background: Head and Neck Squamous Cell Carcinoma (HNSCC) is one of the most common malignancies globally. An early diagnosis of this disease is crucial, and the detection of gene mutations in circulating tumour DNA (ctDNA) through a liquid biopsy is a promising non-invasive diagnostic method. This review aims to provide an overview of ctDNA mutations in HNSCC patients and discuss the potential use of this tool in diagnosis and prognosis. (2) Methods: A systematic search for articles published in the English language between January 2000 and April 2021 in the Medline and Scopus databases was conducted. (3) Results: A total of 10 studies published in nine publications were selected and analysed. Altogether, 390 samples were obtained from HNSCC patients, and 79 control samples were evaluated. The most often explored gene mutation in ctDNA was TP53. (4) Conclusions: The examination of a larger group of gene mutations and the use of a combination of multiple detection methods contribute to a higher detection rate of mutated ctDNA. More studies are necessary to verify these conclusions and to translate them into clinical practice.

Department of Otorhinolaryngology and Head and Neck Surgery 1st Medical Faculty Motol University Hospital 15000 Prague Czech Republic

Department of Otorhinolaryngology and Head and Neck Surgery Faculty of Medicine Masaryk University and St Anne's University Hospital 65691 Brno Czech Republic

Zobrazit více v PubMed

Johnson D.E., Burtness B., Leemans C.R., Lui V.W.Y., Bauman J.E., Grandis J.R. Head and neck squamous cell carcinoma. Nat. Rev. Dis Primers. 2020;6:92. doi: 10.1038/s41572-020-00224-3. PubMed DOI PMC

Marur S., Forastiere A.A. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin. Proc. 2016;91:386–396. doi: 10.1016/j.mayocp.2015.12.017. PubMed DOI

Schmidt H., Kulasinghe A., Allcock R.J.N., Tan L.Y., Mokany E., Kenny L., Punyadeera C. A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer. Diagnostics (Basel) 2018;8:79. doi: 10.3390/diagnostics8040079. PubMed DOI PMC

Lajer C.B., von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS. 2010;118:510–519. doi: 10.1111/j.1600-0463.2010.02624.x. PubMed DOI

Ang K.K., Harris J., Wheeler R., Weber R., Rosenthal D.I., Nguyen-Tan P.F., Westra W.H., Chung C.H., Jordan R.C., Lu C., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 2010;363:24–35. doi: 10.1056/NEJMoa0912217. PubMed DOI PMC

Chow L.Q.M. Head and Neck Cancer. N. Engl. J. Med. 2020;382:60–72. doi: 10.1056/NEJMra1715715. PubMed DOI

Hwang I., Choi S.H., Kim Y.J., Kim K.G., Lee A.L., Yun T.J., Kim J.H., Sohn C.H. Differentiation of recurrent tumor and posttreatment changes in head and neck squamous cell carcinoma: Application of high b-value diffusion-weighted imaging. AJNR Am. J. Neuroradiol. 2013;34:2343–2348. doi: 10.3174/ajnr.A3603. PubMed DOI PMC

van Ginkel J.H., Huibers M.M.H., Noorlag R., de Bree R., van Es R.J.J., Willems S.M. Liquid Biopsy: A Future Tool for Posttreatment Surveillance in Head and Neck Cancer? Pathobiology. 2017;84:115–120. doi: 10.1159/000452861. PubMed DOI

Schmidt H., Kulasinghe A., Perry C., Nelson C., Punyadeera C. A liquid biopsy for head and neck cancers. Expert Rev. Mol. Diagn. 2016;16:165–172. doi: 10.1586/14737159.2016.1127758. PubMed DOI

Siravegna G., Marsoni S., Siena S., Bardelli A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 2017;14:531–548. doi: 10.1038/nrclinonc.2017.14. PubMed DOI

Ribeiro I.P., de Melo J.B., Carreira I.M. Head and neck cancer: Searching for genomic and epigenetic biomarkers in body fluids–the state of art. Mol. Cytogenet. 2019;12:33. doi: 10.1186/s13039-019-0447-z. PubMed DOI PMC

Mandel P. Les acides nucléiques du plasma sanguin chez l’homme. C R Seances Soc. Biol. Fil. 1948;142:241–243. PubMed

Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–650. PubMed

Gormally E., Caboux E., Vineis P., Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mutat. Res. 2007;635:105–117. doi: 10.1016/j.mrrev.2006.11.002. PubMed DOI

Lousada-Fernandez F., Rapado-Gonzalez O., Lopez-Cedrun J.L., Lopez-Lopez R., Muinelo-Romay L., Suarez-Cunqueiro M.M. Liquid Biopsy in Oral Cancer. Int J. Mol. Sci. 2018;19:1704. doi: 10.3390/ijms19061704. PubMed DOI PMC

Chang Y., Tolani B., Nie X., Zhi X., Hu M., He B. Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring. Ther. Clin. Risk Manag. 2017;13:1363–1374. doi: 10.2147/TCRM.S141991. PubMed DOI PMC

Chan J.Y.K., Zhen G., Agrawal N. The role of tumor DNA as a diagnostic tool for head and neck squamous cell carcinoma. Semin. Cancer Biol. 2019;55:1–7. doi: 10.1016/j.semcancer.2018.07.008. PubMed DOI

Alix-Panabieres C., Pantel K. Real-time liquid biopsy: Circulating tumor cells versus circulating tumor DNA. Ann. Transl. Med. 2013;1:18. doi: 10.3978/j.issn.2305-5839.2013.06.02. PubMed DOI PMC

Holdhoff M., Schmidt K., Donehower R., Diaz L.A., Jr. Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J. Natl. Cancer Inst. 2009;101:1284–1285. doi: 10.1093/jnci/djp240. PubMed DOI

Payne K., Spruce R., Beggs A., Sharma N., Kong A., Martin T., Parmar S., Praveen P., Nankivell P., Mehanna H. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma. Head Neck. 2018;40:1598–1604. doi: 10.1002/hed.25140. PubMed DOI

Crowley E., Di Nicolantonio F., Loupakis F., Bardelli A. Liquid biopsy: Monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 2013;10:472–484. doi: 10.1038/nrclinonc.2013.110. PubMed DOI

Thierry A.R., El Messaoudi S., Gahan P.B., Anker P., Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35:347–376. doi: 10.1007/s10555-016-9629-x. PubMed DOI PMC

Vasioukhin V., Anker P., Maurice P., Lyautey J., Lederrey C., Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br. J. Haematol. 1994;86:774–779. doi: 10.1111/j.1365-2141.1994.tb04828.x. PubMed DOI

Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., Diaz L.A., Jr., Goodman S.N., David K.A., Juhl H., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA. 2005;102:16368–16373. doi: 10.1073/pnas.0507904102. PubMed DOI PMC

van Ginkel J.H., Huibers M.M.H., van Es R.J.J., de Bree R., Willems S.M. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients. BMC Cancer. 2017;17:428. doi: 10.1186/s12885-017-3424-0. PubMed DOI PMC

Schmidt H., Kulasinghe A., Kenny L., Punyadeera C. The development of a liquid biopsy for head and neck cancers. Oral Oncol. 2016;61:8–11. doi: 10.1016/j.oraloncology.2016.07.014. PubMed DOI

Porter A., Natsuhara M., Daniels G.A., Patel S.P., Sacco A.G., Bykowski J., Banks K.C., Cohen E.E.W. Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients. Transl. Cancer Res. 2020;9:203–209. doi: 10.21037/tcr.2019.12.70. PubMed DOI PMC

Chan K.C., Yeung S.W., Lui W.B., Rainer T.H., Lo Y.M. Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin. Chem. 2005;51:781–784. doi: 10.1373/clinchem.2004.046219. PubMed DOI

Swinkels D.W., Wiegerinck E., Steegers E.A., de Kok J.B. Effects of blood-processing protocols on cell-free DNA quantification in plasma. Clin. Chem. 2003;49:525–526. doi: 10.1373/49.3.525. PubMed DOI

Ignatiadis M., Lee M., Jeffrey S.S. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. Clin. Cancer Res. 2015;21:4786–4800. doi: 10.1158/1078-0432.CCR-14-1190. PubMed DOI

Wang Y., Springer S., Mulvey C.L., Silliman N., Schaefer J., Sausen M., James N., Rettig E.M., Guo T., Pickering C.R., et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci. Transl. Med. 2015;7:293ra104. doi: 10.1126/scitranslmed.aaa8507. PubMed DOI PMC

Perdomo S., Avogbe P.H., Foll M., Abedi-Ardekani B., Facciolla V.L., Anantharaman D., Chopard P., Calvez-Kelm F.L., Vilensky M., Polesel J., et al. Circulating tumor DNA detection in head and neck cancer: Evaluation of two different detection approaches. Oncotarget. 2017;8:72621–72632. doi: 10.18632/oncotarget.20004. PubMed DOI PMC

Galot R., van Marcke C., Helaers R., Mendola A., Goebbels R.M., Caignet X., Ambroise J., Wittouck K., Vikkula M., Limaye N., et al. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2020;104:104631. doi: 10.1016/j.oraloncology.2020.104631. PubMed DOI

Coulet F., Blons H., Cabelguenne A., Lecomte T., Lacourreye O., Brasnu D., Beaune P., Zucman J., Laurent-Puig P. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res. 2000;60:707–711. PubMed

Schwaederle M., Chattopadhyay R., Kato S., Fanta P.T., Banks K.C., Choi I.S., Piccioni D.E., Ikeda S., Talasaz A., Lanman R.B., et al. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017;77:5419–5427. doi: 10.1158/0008-5472.CAN-17-0885. PubMed DOI PMC

Jung M., Klotzek S., Lewandowski M., Fleischhacker M., Jung K. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin. Chem. 2003;49:1028–1029. doi: 10.1373/49.6.1028. PubMed DOI

Perez Sayans M., Chamorro Petronacci C.M., Lorenzo Pouso A.I., Padin Iruegas E., Blanco Carrion A., Suarez Penaranda J.M., Garcia Garcia A. Comprehensive Genomic Review of TCGA Head and Neck Squamous Cell Carcinomas (HNSCC) J. Clin. Med. 2019;8:1896. doi: 10.3390/jcm8111896. PubMed DOI PMC

Brennan J.A., Boyle J.O., Koch W.M., Goodman S.N., Hruban R.H., Eby Y.J., Couch M.J., Forastiere A.A., Sidransky D. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 1995;332:712–717. doi: 10.1056/NEJM199503163321104. PubMed DOI

Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157–1160. doi: 10.1126/science.1208130. PubMed DOI PMC

Mahoney P.A., Weber U., Onofrechuk P., Biessmann H., Bryant P.J., Goodman C.S. The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily. Cell. 1991;67:853–868. doi: 10.1016/0092-8674(91)90359-7. PubMed DOI

Tanoue T., Takeichi M. New insights into Fat cadherins. J. Cell Sci. 2005;118:2347–2353. doi: 10.1242/jcs.02398. PubMed DOI

Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., Fakhry C., Xie T.X., Zhang J., Wang J., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154–1157. doi: 10.1126/science.1206923. PubMed DOI PMC

Miracca E.C., Kowalski L.P., Nagai M.A. High prevalence of p16 genetic alterations in head and neck tumours. Br. J. Cancer. 1999;81:677–683. doi: 10.1038/sj.bjc.6690747. PubMed DOI PMC

Whiting P.F., Rutjes A.W., Westwood M.E., Mallett S., Deeks J.J., Reitsma J.B., Leeflang M.M., Sterne J.A., Bossuyt P.M., QUADAS-2 Group QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 2011;155:529–536. doi: 10.7326/0003-4819-155-8-201110180-00009. PubMed DOI

Mes S.W., Brink A., Sistermans E.A., Straver R., Oudejans C.B.M., Poell J.B., Leemans C.R., Brakenhoff R.H. Comprehensive multiparameter genetic analysis improves circulating tumor DNA detection in head and neck cancer patients. Oral Oncol. 2020;109:104852. doi: 10.1016/j.oraloncology.2020.104852. PubMed DOI

Braig F., Voigtlaender M., Schieferdecker A., Busch C.J., Laban S., Grob T., Kriegs M., Knecht R., Bokemeyer C., Binder M. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. Oncotarget. 2016;7:42988–42995. doi: 10.18632/oncotarget.8943. PubMed DOI PMC

Hieronymus H., Murali R., Tin A., Yadav K., Abida W., Moller H., Berney D., Scher H., Carver B., Scardino P., et al. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife. 2018;7:e37294. doi: 10.7554/eLife.37294. PubMed DOI PMC

Fiala C., Kulasingam V., Diamandis E.P. Circulating Tumor DNA for Early Cancer Detection. J. Appl. Lab. Med. 2018;3:300–313. doi: 10.1373/jalm.2018.026393. PubMed DOI

Wilson H.L., D’Agostino R.B., Jr., Meegalla N., Petro R., Commander S., Topaloglu U., Zhang W., Porosnicu M. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma. Oncologist. 2021;26:e279–e289. doi: 10.1002/onco.13573. PubMed DOI PMC

Tamkovich S.N., Cherepanova A.V., Kolesnikova E.V., Rykova E.Y., Pyshnyi D.V., Vlassov V.V., Laktionov P.P. Circulating DNA and DNase activity in human blood. Ann. N. Y. Acad. Sci. 2006;1075:191–196. doi: 10.1196/annals.1368.026. PubMed DOI

Cherepanova A.V., Tamkovich S.N., Bryzgunova O.E., Vlassov V.V., Laktionov P.P. Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors. Ann. N. Y. Acad. Sci. 2008;1137:218–221. doi: 10.1196/annals.1448.016. PubMed DOI

Kim Y.W., Kim Y.H., Song Y., Kim H.S., Sim H.W., Poojan S., Eom B.W., Kook M.C., Joo J., Hong K.M. Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer. Exp. Mol. Med. 2019;51:1–10. doi: 10.1038/s12276-019-0292-5. PubMed DOI PMC

Sarkozy C., Huet S., Carlton V.E., Fabiani B., Delmer A., Jardin F., Delfau-Larue M.H., Hacini M., Ribrag V., Guidez S., et al. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget. 2017;8:8765–8774. doi: 10.18632/oncotarget.14448. PubMed DOI PMC

Tsao S.C., Weiss J., Hudson C., Christophi C., Cebon J., Behren A., Dobrovic A. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci. Rep. 2015;5:11198. doi: 10.1038/srep11198. PubMed DOI PMC

Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., Bartlett B.R., Wang H., Luber B., Alani R.M., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014;6:224ra224. doi: 10.1126/scitranslmed.3007094. PubMed DOI PMC

Dawson S.J., Rosenfeld N., Caldas C. Circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013;369:93–94. doi: 10.1056/NEJMoa1213261. PubMed DOI